Transcriptomic profiling identifies two molecular clusters with distinct immune and proliferative signatures. (IMAGE)
Caption
(A) Study design schematic showing analytical workflow for 46 patients with HCC (AA, n=15; nonAA, n=31) including gene expression profiling, mutation analysis, survival analysis and cluster analysis approaches. (B) Heatmap displaying expression Z scores of 126 differentially expressed genes (p<0.001 for AA vs nonAA comparison) across HCC tumour samples, hierarchically clustered into two race-associated clusters (RC1, RC2). Clinical annotations show race category (AA vs nonAA), sex, BMI, AFP levels (≤20 vs >20 ng/mL), cirrhosis status, viral hepatitis status (HBV or HCV) and alcohol abuse history. Genes and samples were clustered using Ward’s linkage method based on Pearson correlation distances. Highlighted genes represent top upregulated and downregulated genes in AA versus nonAA comparison. (C) Pathway enrichment analysis comparing RC1 and RC2 clusters. RC2 shows enrichment of immune related pathways (allograft rejection, IFN-γ response, inflammatory response), while RC1 shows enrichment of proliferative pathways (MYC Targets) with enrichment shown as log2FC. (D) RECIST version 1.1 response rates by molecular cluster showing differential immunotherapy response between RC1 (n=28) and RC2 (n=18) clusters. AA, African American; AFP, alpha-fetoprotein, BMI, body mass index; FC, fold change; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; nonAA, non-African American.
Credit
By Aryan Neupane, Anuradha Budhu, Farid Rashidi Mehrabadi, et al.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC